Laboratory Corp of America Holdings Stock News

Investors are optimistic about Labcorp (LH) on the continued strength of Central Labs, which is driving the success of the biopharma segment.

The recent deal will augment Labcorp's (LH) laboratory services network and expand access to the company's high-quality clinical laboratory services.

Labcorp's (LH) pTau217 test is a pivotal blood biomarker intended to aid in the diagnosis of Alzheimer's disease.

Labcorp (LH) continues to progress in terms of integrating hospital partnerships and acquisitions.

Investors interested in Medical - Dental Supplies stocks are likely familiar with Labcorp (LH) and The Cooper Companies (COO). But which of these two stocks offers value investors a better bang for th

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest

Labcorp's (LH) Weight Loss Management service includes proven tests from its extensive menu and simplifies the procedure for both physicians and patients.

Targeted development in high-growth areas and strategic partnerships bode well for Labcorp (LH).

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest

Labcorp (LH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Investors looking for stocks in the Medical - Dental Supplies sector might want to consider either Labcorp (LH) or The Cooper Companies (COO). But which of these two companies is the best option for t

Although the revenue and EPS for Labcorp (LH) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street

Labcorp (LH) came out with quarterly earnings of $3.30 per share, beating the Zacks Consensus Estimate of $3.29 per share. This compares to earnings of $3.05 per share a year ago.

Labcorp (LH) came out with quarterly earnings of $3.30 per share, beating the Zacks Consensus Estimate of $3.29 per share. This compares to earnings of $3.05 per share a year ago.

Strength in Diagnostics Laboratories and Biopharma Laboratory Services businesses contributes to Labcorp's (LH) Q4 performance.